Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN) has been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.57.

Several research firms have recently commented on MRSN. Citigroup assumed coverage on shares of Mersana Therapeutics in a report on Friday, November 15th. They set a “buy” rating and a $5.00 price target on the stock. Wedbush restated an “outperform” rating and issued a $4.00 target price (down previously from $7.00) on shares of Mersana Therapeutics in a research note on Friday, January 10th.

Hedge Funds Weigh In On Mersana Therapeutics

Several institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. bought a new stake in shares of Mersana Therapeutics during the 4th quarter worth about $37,000. SG Americas Securities LLC boosted its position in Mersana Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after purchasing an additional 25,058 shares during the period. Avanza Fonder AB acquired a new position in Mersana Therapeutics during the fourth quarter valued at approximately $81,000. JPMorgan Chase & Co. raised its position in shares of Mersana Therapeutics by 18.9% in the third quarter. JPMorgan Chase & Co. now owns 2,351,359 shares of the company’s stock valued at $4,444,000 after purchasing an additional 374,460 shares during the period. Finally, Exome Asset Management LLC acquired a new stake in shares of Mersana Therapeutics in the third quarter worth $2,227,000. 93.92% of the stock is currently owned by institutional investors.

Mersana Therapeutics Stock Up 6.7 %

NASDAQ:MRSN opened at $0.64 on Wednesday. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 1-year low of $0.49 and a 1-year high of $6.28. The business’s fifty day moving average price is $1.56 and its 200 day moving average price is $1.77. The firm has a market capitalization of $79.55 million, a price-to-earnings ratio of -1.06 and a beta of 1.43.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Wednesday, November 13th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.08. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The business had revenue of $12.60 million during the quarter, compared to analysts’ expectations of $7.53 million. During the same period last year, the company posted ($0.35) earnings per share. The firm’s quarterly revenue was up 63.6% compared to the same quarter last year. On average, sell-side analysts forecast that Mersana Therapeutics will post -0.61 earnings per share for the current fiscal year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.